Note 14 - Licensing Agreement (Detail) (USD $)	3 Months Ended	12 Months Ended			12 Months Ended		0 Months Ended			0 Months Ended
	Dec. 31, 2008	Dec. 31, 2011	Dec. 31, 2012	Jan. 31, 2011	Dec. 31, 2011 Requires Enrollment of Patients [Member]	Dec. 31, 2011 Preferred Equity Financing [Member]	Jan. 18, 2013 Non-Refundable Research and Development Fee (Member)	Jan. 18, 2013 Additional Fee (Member)	Dec. 31, 2012 Costs Reimbursable to Hisun (Member)	Jan. 18, 2013 Cancellation of Exclusive Option Agreement (Member)
Proceeds from License Fees Received	$ 2,500,000						$ 5,000,000	$ 5,000,000
Receivables, Long-term Contracts or Programs				4,000,000
Revenue Recognition, Milestone Method, Revenue Recognized					2,000,000	2,000,000
Percentage Reduction on Milestone Payments		40.00%
Other Accrued Liabilities, Current		$ 2,031,934	$ 1,254,979						$ 326,000
Research and Development Arrangement, Contract to Perform for Others, Description and Terms										$5